<SEC-DOCUMENT>0001193125-20-108190.txt : 20200415
<SEC-HEADER>0001193125-20-108190.hdr.sgml : 20200415
<ACCEPTANCE-DATETIME>20200415170605
ACCESSION NUMBER:		0001193125-20-108190
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20200415
DATE AS OF CHANGE:		20200415
EFFECTIVENESS DATE:		20200415

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			INOVIO PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001055726
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				330969592
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14888
		FILM NUMBER:		20794352

	BUSINESS ADDRESS:	
		STREET 1:		6769 MESA RIDGE RD.
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		8584103134

	MAIL ADDRESS:	
		STREET 1:		6769 MESA RIDGE RD.
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INOVIO BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20050404

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20011116

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL LTD
		DATE OF NAME CHANGE:	19980213
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>d918910ddefa14a.htm
<DESCRIPTION>DEFA14A
<TEXT>
<HTML><HEAD>
<TITLE>DEFA14A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 14A
INFORMATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Proxy Statement Pursuant to Section&nbsp;14(a) of </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>the Securities Exchange Act of 1934 (Amendment No. &nbsp;&nbsp;&nbsp;&nbsp;) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filed by the Registrant&nbsp;&nbsp;&#9746; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filed by a Party
other than the Registrant&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Preliminary Proxy Statement </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Confidential, for Use of the Commission Only (as permitted by Rule
<FONT STYLE="white-space:nowrap">14a-6(e)(2))</FONT></B> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Definitive Proxy Statement </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9746;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Definitive Additional Materials </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting Material under <FONT STYLE="white-space:nowrap">&#167;240.14a-12</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>INOVIO PHARMACEUTICALS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Name of Registrant as Specified In Its Charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Name of Person(s) Filing Proxy Statement, if other than the Registrant) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payment of Filing Fee (Check the appropriate box): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9746;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No fee required. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Fee computed on table below per Exchange Act Rules <FONT STYLE="white-space:nowrap">14a-6(i)(1)</FONT> and <FONT
STYLE="white-space:nowrap">0-11.</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Title of each class of securities to which transaction applies: </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;margin-left:9%;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Aggregate number of securities to which transaction applies: </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;margin-left:9%;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule <FONT
STYLE="white-space:nowrap">0-11</FONT> (set forth the amount on which the filing fee is calculated and state how it was determined): </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;margin-left:9%;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Proposed maximum aggregate value of transaction: </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;margin-left:9%;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Total fee paid: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;margin-left:9%;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Fee paid previously with preliminary materials. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Check box if any part of the fee is offset as provided by Exchange Act Rule
<FONT STYLE="white-space:nowrap">0-11(a)(2)</FONT> and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amount Previously Paid: </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;margin-left:9%;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Form, Schedule or Registration Statement No.: </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;margin-left:9%;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Filing Party: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;margin-left:9%;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Date Filed: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;margin-left:9%;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g918910g39v28.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SUPPLEMENT TO </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTICE OF THE 2020 ANNUAL MEETING OF STOCKHOLDERS AND PROXY STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DATED MARCH&nbsp;27, 2020 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR THE ANNUAL MEETING OF STOCKHOLDERS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TO BE HELD ON MAY&nbsp;14, 2020 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
March&nbsp;27, 2020, Inovio Pharmaceuticals, Inc. (&#147;<B><I>Inovio</I></B>&#148;) filed a definitive proxy statement (the &#147;<B><I>Proxy Statement</I></B>&#148;) with the Securities and Exchange Commission in connection with its Annual Meeting
of Stockholders to be held on May&nbsp;14, 2020. On April&nbsp;15, 2020, Inovio issued a press release announcing that its Annual Meeting of Stockholders will now be held by means of a virtual format only and at a new time. The press release is
being filed herewith as definitive additional material. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The press release should be read in conjunction with the Proxy Statement. </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INOVIO to Host its Annual Meeting of Stockholders in Virtual Format and at a New Time </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PLYMOUTH MEETING, Pa., April&nbsp;15, 2020 &#151; INOVIO Pharmaceuticals, Inc. (NASDAQ:INO) today announced that due to the public health and safety concerns
related to the novel coronavirus <FONT STYLE="white-space:nowrap">(COVID-19)</FONT> pandemic and recommendations and orders from federal and state governmental authorities, its Annual Meeting of Stockholders (the 2020 Annual Meeting) will now be
held by means of a virtual format only and will be held at a new time at 2:00 pm Eastern Time. The date of the meeting (May 14, 2020), as disclosed in INOVIO&#146;s proxy statement for the meeting, has not changed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Online access to the meeting will begin at 1:45 pm Eastern Time. Stockholders will not be able to attend the meeting in person. The virtual format of the 2020
Annual Meeting will provide stockholders with the same rights and opportunities to participate as they would have at an <FONT STYLE="white-space:nowrap">in-person</FONT> meeting. If you plan to attend the meeting, please check
<U>http://ir.inovio.com/investors</U> for updates prior to the meeting date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As always, whether or not you plan to attend the 2020 Annual Meeting, you
are encouraged to vote your shares prior to the meeting by one of the methods described in the proxy materials for the meeting. If you have already voted, you do not need to vote again. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Attending the Virtual Meeting </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You can attend the meeting
by accessing <U>www.virtualshareholdermeeting.com/INO2020</U> and entering the <FONT STYLE="white-space:nowrap">16-digit</FONT> control number on the proxy card you previously received; if you hold your shares in &#147;street name&#148; (i.e.,
through an account at a broker or other nominee), please follow your broker&#146;s or nominee&#146;s instructions you previously received to obtain your <FONT STYLE="white-space:nowrap">16-digit</FONT> control number or otherwise attend through the
broker or nominee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A list of INOVIO&#146;s stockholders of record will be available for examination by stockholders on the meeting website during the
meeting. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Asking Questions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you wish to submit a question, you may ask a question before the meeting beginning at 9:00 am Eastern Time, on April&nbsp;20, 2020, and until 11:59 pm
Eastern Time, on May&nbsp;13, 2020. To submit a question, you may log into <U>www.proxyvote.com</U> and enter your <FONT STYLE="white-space:nowrap">16-digit</FONT> control number. Once past the login screen, click on &#147;Question for
Management,&#148; type in your question, and click &#147;Submit.&#148; Only questions pertinent to meeting matters will be answered during the meeting, subject to time constraints. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Voting Shares at the Virtual Meeting </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you have not
voted your shares prior to the meeting, you will be able to vote your shares electronically at the 2020 Annual Meeting by clicking &#147;Vote Here&#148; on the meeting website. Whether or not you plan to attend the meeting, you are encouraged to
vote your shares prior to the meeting by one of the methods described in the proxy materials you previously received. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The proxy materials you previously
received may continue to be used to vote your shares in connection with the meeting. The previously distributed proxy materials will not be updated to reflect the change to a virtual format or change in time. If you have already voted, you do not
need to vote again. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About INOVIO </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">INOVIO is a
biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure, and protect people from diseases associated with HPV, cancer, and infectious diseases. INOVIO is the first and only company to have
clinically demonstrated that a DNA medicine can be delivered directly into cells in the body via a proprietary smart device to produce a robust and tolerable immune response. Specifically, INOVIO&#146;s lead candidate
<FONT STYLE="white-space:nowrap">VGX-3100,</FONT> currently in Phase 3 trials for precancerous cervical dysplasia, destroyed and cleared high-risk HPV 16 and 18 in a Phase 2b clinical trial. High-risk HPV is responsible for 70% of cervical cancer,
90% of anal cancer, and 69% of vulvar cancer. Also in development are programs targeting <FONT STYLE="white-space:nowrap">HPV-related</FONT> cancers and a rare <FONT STYLE="white-space:nowrap">HPV-related</FONT> disease, recurrent respiratory
papillomatosis (RRP); <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">non-HPV-related</FONT></FONT> cancers glioblastoma multiforme (GBM) and prostate cancer; as well as externally funded infectious disease DNA vaccine development
programs in Zika, Lassa fever, Ebola, HIV, and coronaviruses associated with MERS and <FONT STYLE="white-space:nowrap">COVID-19</FONT> diseases. Partners and collaborators include Advaccine, ApolloBio Corporation, AstraZeneca, The Bill&nbsp;&amp;
Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA)/DOD, GeneOne Life Science/VGXI, HIV Vaccines Trial Network, Medical CBRN Defense Consortium (MCDC), National Cancer
Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, Plumbline Life Sciences, Regeneron, Roche/Genentech, University of Pennsylvania, Walter Reed Army Institute of Research, and The
Wistar Institute. INOVIO also is a proud recipient of 2020 Women on Boards &#147;W&#148; designation recognizing companies with more than 20% women on their board of directors. For more information, visit www.inovio.com. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CONTACTS: </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">Investors:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Ben Matone, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">484-362-0076,</FONT></FONT>
<U>ben.matone@inovio.com</U> </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">Media:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Jeff Richardson, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">267-440-4211,</FONT></FONT>
<U>jrichardson@inovio.com</U> </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="96%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt; padding-right:2pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Important Notice Regarding the Availability of Proxy Materials for the 2020 Annual Meeting of Stockholders</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>to be held on May&nbsp;14, 2020 virtually via live audio-only webcast at</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>www.virtualshareholdermeeting.com/INO2020.</B></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The Proxy Statement and our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31,
2019, as</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>filed with the Securities and Exchange Commission, are available at www.proxyvote.com.</B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">April&nbsp;15, 2020 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By order of the Board of Directors </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g918910g44x13.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">J. Joseph Kim, Ph.D. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Chief
Executive Officer </I></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g918910g39v28.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g918910g39v28.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!X17AI9@  34T *@    @ !@$Q  (
M   1    5@,!  4    !    : ,#  $    !     %$0  $    ! 0   %$1
M  0    !   .Q%$2  0    !   .Q     !-:6-R;W-O9G0@3V9F:6-E
M 8:@  "QC__; $,  @$! @$! @(" @(" @(#!0,# P,#!@0$ P4'!@<'!P8'
M!P@)"PD(" H(!P<*#0H*"PP,# P'"0X/#0P."PP,#/_; $,! @(" P,#!@,#
M!@P(!P@,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,#/_  !$( %P!@0,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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M[6;^X?TKUR@ HHHH **\R^/'[8GPY_9L@;_A+/$UC97FW<EA$3/>2#MB),L
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M[ ]I_P"B4H Z2O./VI?C;)\"OA7-J=I''-JUY*MEI\;C<#,P)W$=]JJQQW(
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MR('Q$_Z_K/\ ]!FK[^EE6")I'951 69B<  =37P#_P $$O\ D0/B)_U_6?\
MZ#-7UU^UYXSD^'W[+GQ UB'BXL]"NS"1VD:)E4_]],* /SF^!VEM_P %#/\
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$% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g918910g44x13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g918910g44x13.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MP  +"  W &\! 1$ _\0 'P   04! 0$! 0$           $" P0%!@<("0H+
M_\0 M1   @$# P($ P4%! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$(
M(T*QP152T? D,V)R@@D*%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%56
M5UA96F-D969G:&EJ<W1U=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBI
MJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W
M^/GZ_]H " $!   _ /9J****************YGQ%KUY:W;0Z:4"V0BFNV=-P
M97<*(QSPQ&3GG&!ZUTU%%%%%%%%%%8GBKQ*GA:QMKVX@:2U>Y2&>13_J4;/S
MGU ./SK8::-(#,SJ(@N\MGC&,YK@]$?_ (22,) S2)?78U"_F7E$C!!B@#=V
MPJ9 Z '/6N_KE/%.J2S"^LK:>2WM[*U:XOIX6VN/E)2)&[,<9)Z@8]:W=$CG
MAT*PCNW:2X2WC$KL<EFVC)/XU>HHHHHHHJ"\L[?4+26UO(4FMY5VO&XRK#W%
M><2:1#_8::-+>:D]W)?_ -G")KU]NP-N+!<\CROPKTBUM8+*VCM[6&.&&,;4
MCC4*JCV JKJNN:?HD/F:A=10EE9D1W :3:,D*#U-<M+9/<:3IVE70\N^UVZ^
MV7J]PBD2.OX )'787^H6NF6;W5[,L,"=6;] !W/L*Q)_%-W:Q"^NM%GM])!&
M^XDD EC4_P ;1#D*._.0.<5T88, 5((/(([TM%%%%%9VKZL-,2&.*%KF\N6*
M6]NIP7.,DD]E Y)[?7 KS'Q'HOB&;QM<ZGID%M?:C:VB^;Y64%M(WW#'EOG;
M:O.<9!Y'-=@?#^NQ7=C<V6INMS/$XU">X8R $A2NR+(48.0,8XZYK*\:)-Y>
M@OK$4$M_%<;K@6Q/EM:AE\PD,,]?+./7C-;>HO?67C7[9'I=U?(U@(+8P[0J
M/O)?<Q/RY 3GVJ]8:)-->)J6N2+<7BG,,*_ZFU_W!W;U<\^F!Q6Q+$D\+Q2H
M'CD4JRL."#P0:Y73=:@\)0?V1X@N# EM\MI=R@[)X?X1NZ;U'RD'T![U<'C"
MVO05T.UN]4D[&*,I$/K(^%Q],TOV+Q'J0!N]1@TR(]8K)/,DQ[R., _1:4^#
M=/E'^E7&IW3==TM_+G\@P'Z59L?#=GIMPDMI-?(%S^[:[D=&^H8FM:BN8M[R
M%?$FOZK?2".WTV-+9&;HB[!)(?Q++_WR*M^%+6>/3)+V]39=ZC,UU(A'*!ON
M(?\ =0*/P-;E>?\ B7.H:SJ7E,=X:STN,  C<\@ED_\ '=OY5Z!112$!A@@$
M>]'2EHHHHK$NO"ME>:PU_+)<%'9));4/^YED3[CLN.2..,X.!D<5MT5S5GX:
GND\137EW<PR6:W3W<$:H0YD9 F7/3Y0"!CUYZ5TM%%%%%%%%?__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
